This archived webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.

Despite common and occasionally serious side effects, androgen deprivation therapy (ADT) is widely used in the management of prostate cancer at all stages and presentations.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.

This webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.

This information was originally presented on March 15, 2012, at the NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida.
 

The molecular analysis of biomarkers in oncology is rapidly advancing, but the incorporation of new molecular tests into clinical practice will require a greater understanding of the genetic changes that drive malignancy, the assays used to measure the resulting phenotypes and genotypes, and the

This congress is a full-day educational program designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Bladder, Kidney, and Prostate Cancers.

This information was originally presented on March 15, 2012, at the NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida.